NEW YORK (GenomeWeb News) – Biosearch Technologies announced today it has exclusively licensed a single-molecule fluorescent in situ hybridization technology from the University of Medicine and Dentistry of New Jersey.
Biosearch gained the exclusive rights to manufacture, catalogue, and sell validated RNA FISH probes, assays, and kits in the research, applied markets, and in vitro diagnostic fields under the UMDNJ technologies and patents applications. Terms of the agreement were not disclosed.
In a statement, Marc Beal, director of corporate development for Biosearch, said that his company's expertise in fluorescence and fluorescent oligonucleotide manufacturing coupled with the technology licensed from UMDNJ "will allow Biosearch to quickly penetrate the marketplace with both assays and kits."
Headquartered in Novato, Calif., Biosearch synthesizes oligonucleotides. The company also offers fluorogenic probes and primers, DNA and RNA synthesis reagents, and other materials for genomic research.